Welcome to our dedicated page for Halberd news (Ticker: HALB), a resource for investors and traders seeking the latest updates and insights on Halberd stock.
Halberd Corporation (HALB) is an innovative biopharmaceutical company developing targeted therapies for PTSD, traumatic brain injury, and related mental health conditions through patented drug formulations and wearable monitoring technologies. This news hub provides investors and researchers with timely updates on the company's clinical trials, intellectual property developments, and strategic partnerships.
Access authoritative information about HALB's progress in mental health treatment innovation, including updates on its LDN+ and Tri-Ax nasal spray therapies. The repository consolidates press releases related to CRADA clinical trials, technology integrations with partners like Athena GTX, and patent filings that underpin the company's valuation.
Key content categories include regulatory milestones, research collaborations with military healthcare providers, and advancements in combined pharmaceutical/digital health solutions. All materials maintain compliance with OTC Market disclosure standards while emphasizing HALB's unique position at the intersection of biopharma and wearable diagnostics.
Bookmark this page for streamlined tracking of HALB's progress in addressing critical mental health challenges through evidence-based therapeutic innovation. Check regularly for verified updates that reflect the company's commitment to advancing both patient care and shareholder value.
Halberd Corporation announced a breakthrough in treating Candida auris, a multidrug-resistant fungal pathogen, using a novel extracorporeal method that combines lasers and metallic nanoparticles. This method has shown success in eradicating the fungus in as little as 5 minutes. Dr. Cooper from Youngstown State University emphasized the treatment's potential to mitigate the public health threat posed by such infections. Halberd has also previously demonstrated similar effectiveness against Escherichia coli and antibiotic-resistant bacteria, reinforcing its technology's versatility and potential impact on healthcare costs and patient outcomes.
Halberd Corporation (OTC PINK:HALB) recently showcased its innovative extracorporeal laser eradication process, successfully eliminating antibiotic-resistant bacteria from CDC samples. Conducted at Youngstown State University (YSU), the research led by Professors Dr. Chester Cooper and Dr. W. Gregg Sturrus, emphasizes the effectiveness of their method, which eradicates targeted bacteria in under ten minutes. Halberd's patented technology presents a significant advancement over traditional antibiotic treatments, which often require ten days. The company aims to continue demonstrating the efficacy of its process against various pathogens, potentially revolutionizing future medical treatments.
Halberd Corporation (OTC PINK:HALB) announced animal testing of its patent-pending nasal spray at Mississippi State University to address the effects of Traumatic Brain Injury (TBI). This research follows successful in vitro results in collaboration with Youngstown State University and aims to mitigate TBI-related neurological complications such as PTSD. The triple-action nasal spray can be administered promptly post-injury to potentially reduce long-term damage. Funding for the animal testing program has been secured, with Dr. Russell Carr overseeing the research.
Halberd Corporation (OTC PINK:HALB) has partnered with Mississippi State University to conduct animal testing on novel therapies aimed at mitigating traumatic brain injury effects. The research will be led by the College of Veterinary Medicine and the Department of Biomedical Engineering at the university. Dr. Russell Carr expressed enthusiasm for the collaboration's potential outcomes. Halberd, since its restructuring in 2020, has secured exclusive rights to three patents and filed 22 related applications to enhance shareholder value. Further details regarding the testing scope and timeline are expected to follow.
Halberd Corporation (OTC PINK:HALB) made significant strides in the second half of 2022, including a 44.4% enhancement in COVID-19 antibody effectiveness and the establishment of Halberd Cancer Therapeutics, LTD. The company demonstrated control over PD-1, a key cancer protein, and formed strategic alliances to develop longevity treatments. Halberd's monoclonal antibody showed efficacy against antibiotic-resistant bacteria. The firm aims to restore compliance with SEC filing and is pursuing government contracts. Leadership focuses on R&D to secure future partnerships with Big Pharma.
Halberd Corporation (OTC PINK:HALB) has received antibiotic-resistant bacteria (ARB) strains from the CDC for testing its laser eradication technology. Previously reported successes on multiple Gram-Negative bacteria have paved the way for this new phase of testing. The CDC's collaboration emphasizes the potential military applications against bio-weapons. CEO William A. Hartman highlights the significance of this partnership for national safety and the company's interests. Halberd has made strides in intellectual property with multiple patents and pending applications.
Halberd Corporation has reported the successful application of its patented methodology for Cancer Antigen Eradication Treatment. CEO William Hartman and CTO Mitchell Felder discussed these groundbreaking achievements in an interview. The company's approach involves controlling cancer antigen levels, specifically CTLA-4, to enhance immune response without harmful side effects. This extracorporeal method aims to minimize drug-related fatalities, with over 100,000 deaths annually in the U.S. attributed to medication side effects. Halberd is progressing from in-vitro to in-vivo testing, seeking to advance its innovative treatment.
Halberd Corporation (OTC PINK:HALB) announced a peer-reviewed scientific article demonstrating its novel monoclonal antibody, which significantly boosts the effectiveness of an existing Covid antibody cocktail against the Omicron variant from 65% to over 94%. This achievement underscores the company’s innovative research capabilities. Halberd's antibody showcased effectiveness against all Covid-19 strains tested, indicating its potential for broad application in treating Covid-19. The article is set to be published soon, highlighting Halberd's ongoing commitment to advancing Covid-19 therapies.
Halberd Corporation has achieved significant success in laboratory tests, eradicating five key cancer disease antigens, including CTLA-4, using a patented process with laser emissive energy in under ten minutes. This innovative method aims to eliminate cancer-causing antigens from bodily fluids, potentially offering safer treatments with fewer side effects compared to conventional therapies. The company plans to target the BTLA antigen shortly. Halberd also emphasizes its commitment to reducing treatment costs and improving effectiveness through precise control of cancer antigens.
FAQ
What is the current stock price of Halberd (HALB)?
What is the market cap of Halberd (HALB)?
